tbuckley/cabot-search huggingface dataset:
Reliability and Validity of the Functional Assessment of Cancer Therapy–Ovarian
Authors: Karen Basen-Engquist, Diane Bodurka-Bevers, Mary A. Fitzgerald, Kimberly Webster, David Cella, Shaohua Hu, David M. Gershenson
Journal: Journal of Clinical Oncology (2001)

PURPOSE: To report the reliability and validity of the Functional Assessment of Cancer Therapy–Ovarian (FACT-O) in a consecutive series of outpatients with epithelial ovarian cancer. PATIENTS AND METHODS: Two hundred thirty-two ovarian cancer patients attending an outpatient gynecologic oncology clinic completed questionnaires at baseline. The patients’ FACT-O scores were compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second questionnaire either one week after baseline to assess the instrument’s test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status. RESULTS: Internal consistency and test-retest reliability of the FACT-O were adequate. Overall, the scales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status. CONCLUSION: Overall, the FACT-O provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies.
Venous thromboembolism in patients with brain tumors
Authors: M. S. Dhami, D. Goss, R. Dhami
Journal: Journal of Clinical Oncology (2007)

12528 Venous Thromboembolism (VTE) is common in patients undergoing treatment for brain tumors. American College of Chest Physicians (ACCP) 2004 consensus conference recommends routine use of intermittent pneumatic compression devices (IPC), unfractionated heparin (UH) or low molecular weight heparin (LMWH) for VTE prophylaxis in these patients. There, however, continues to be a reluctance on using pharmacologic VTE prophylaxis in these patients. The goal of our study was to determine the incidence of VTE in patients with brain tumors treated at a community hospital and the frequency of use of thromboprophylaxis in these patients. Both electronic and paper charts of all patients treated for brain tumors between 1997 and 2003 were reviewed. Follow up data was obtained by contacting physicians caring for these patients. Forty two patients were identified (Anaplastic astrocytoma 10; Glioblastoma multiforme 16; Meningioma 15; oligodendroglioma 1). Twelve patients were treated with various adjuvant chemotherapy regimens. Only 16 patients (38%) received any form of VTE prophylaxis. UH (12) or LMWH (2) were used with or without IPCs or graduated compression stockings. There were eight episodes of symptomatic VTE among 42 patients (19%). These include 6 episodes of deep vein thrombosis (DVT) and two cases of superficial vein thrombosis. Three patients with DVT also had symptomatic pulmonary embolus (PE). All episodes VTE were seen in patients with malignant gliomas yielding a 29% incidence of VTE in patients with malignant gliomas. None of the 15 patients with meningioma had symptomatic VTE. All but one episode of VTE were associated with administration of systemic chemotherapy. Half of these episodes occured more than six weeks after surgical debulking. We conclude that incidence of VTE with malignant brain tumors is high (29%) and the administration of chemotherpy increases this risk. There continues to be underutilization of VTE prophylaxis in these patients at very high risk of VTE. Efforts should be directed at improving the understanding of type and duration of appropiate VTE prophylaxis in patients with brain tumors. No significant financial relationships to disclose.
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolamide, interferon alfa, and interleukin-2 for metastatic melanoma
Authors: I. G. Ron, Larisa Ryvo, David Sarid, Noam Asna, Moshe J Inbar
Journal: Journal of Clinical Oncology (2004)

7567 Background: Evaluation of antitumor activity and toxicity of concurrent biochemotherapy that uses cisplatin, vinblastine, temozolamide (Temodal), interferon alfa-2a (IFN-alfa), and interleukin-2 (IL-2) in patients with metastatic melanoma. Methods: Between May 2001 and May 2003, 22 patients with a documented diagnosis of metastatic melanoma with measurable lesions and an Eastern Oncology Cooperative Group (ECOG) performance status of 2 or less were enrolled in this study. Patients were required to have no clinically significant cardiac dysfunction and to be free from symptomatic brain metastases. The treatment consisted of cisplatin 20 mg/m2 daily for 4 days, vinblastine 1.6 mg/m2 daily for 4 days, and oral temozolamide 250 mg/m2 for 5 days, with IL-2 18 × 106 IU/m2 IV decrescendo half dose daily by continuous infusion for 4 days, and IFN-alfa 5 × 106 U/m2 subcutaneously daily for 5 days, repeated at 28-day intervals. Response was assessed after two or three cycles and patients who responded were continued on treatment for a total of seven cycles. Results: Among 22 assessable patients, one patient (4.5%) achieved a complete response (CR) and 10 patients (45.5%) achieved a partial response (PR), for an overall objective response rate of 50%. The median time to disease progression for all patients was 5 months. The median survival of all patients entered into the trial was 7 months. The patient who achieved CR has remained in CR for 13+ months. The toxicity of biochemotherapy consisted of grades 3 and 4 of myelosuppression in 4 patients, grade 3 neutropenic fever in one patient, and grade 4 asthenia in 5 patients; all patients required inpatient hospital care following the 5-day cycle of treatment. Four patients developed renal failure and one of them was treated with hemodialysis. There were no treatment-related deaths. Conclusions: Concurrent biochemotherapy for patients with advanced melanoma is capable of producing high overall response rates and durable remissions in a small fraction of patients. Toxicity, although severe, was manageable in a routine inpatient hospital environment. No significant financial relationships to disclose.
Abstract 339: Capillary Transmitted Light Intensity for the Monitoring of Tissue Perfusion: CLIP Study
Authors: Naoto Morimura, Tetsuya Sakamoto, Kyoko Matsumori, Kohei Takahashi, Tomoki Doi, Tsuyoshi Otsuka, Kyota Nakamura
Journal: Circulation (2014)

Background: We developed a new device for quantifying capillary refill time (CRT) by applying the pulse oximeter principle, and reported the excellent correlation between quantitative CRT (Q-CRT) and tissue hypoperfusion status as represented by arterial blood lactate levels in critically ill patients in the pilot study. Methods: Diagnostic accuracy study was undergone in ICU of a tertiary emergency medical center. While the pulse oxygen saturation sensor was placed on the finger of the patients, transmitted light intensity was measured with a pulse oximeter (OLV-3100, Nihon Kohden Corp., Japan) before start and during compression of the finger. Correlation between delta Ab, defined as the absorbance of light intensity of infra-red (A-ir) minus that of red (A-r), and arterial blood lactate level was analyzed. Results: The delta Ab was analyzed a total of 69 waveforms in 23 patients. The sensitivity, specificity, positive predictive value, and negative predictive value of the delta Ab less than 0.06 for predicting a lactate level more than 2.0 mmol/l were 100%, 93%, 89%, 100%, respectively. Conclusions: The delta Ab was well correlated to high level of blood lactate level in critically ill patients. Further study will confirm to place the delta Ab as one of non-invasive predictors of tissue perfusion status.
Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy
Authors: T. O. Kirby, J. M. Straughn, S. M. Bhoola, R. D. Alvarez, W. K. Huh
Journal: Journal of Clinical Oncology (2004)

5083 Background: Previous studies in taxane/platinum treated patients have shown recurrence rates of ∼50% in all stages after a negative second look laparotomy (SLL); however, they failed to specifically address recurrence rates in advanced stages after negative SLL. This study assessed the risk of recurrence of advanced stage epithelial ovarian cancer patients after complete response to taxane/platinum-based chemotherapy. Methods: Patients with epithelial ovarian cancer treated with taxane/platinum-based chemotherapy from 1994 - 2001 were identified from the medical records. Complete response was defined as having pathologically negative SLL with a post-treatment CA125 of <35 IU. Survival analysis and comparisons were performed using the Kaplan-Meier method and the log rank test. Results: Sixty-six patients with a negative SLL and normal post-treatment CA125 were identified. 37 of the 66 patients (56%) with a negative SLL recurred, and specfically 31 of 43 (72%) stage IIIc/IV patients recurred. Five-year disease free survival (DFS) for stages IIIc/IV was significantly worse than stage I-IIIb (25% vs. 63%, p=0.02). Five-year overall survival was 61% and 87% (p=0.13) for stage IIIc/IV and stage I-IIIb, respectively. Median DFS of stage IIIc/IV was 27 months with a median time to recurrence of 16 months (range 4–61 months). Median follow-up of survivors after SLL was 47 months. Subgroup analysis revealed no significant risk factors for recurrence. Conclusions: Taxane/platinum treated stage IIIc/IV patients who have a negative SLL have high rates of recurrence (72%). Despite complete response to primary therapy, advanced stage disease at initial diagnosis confers a poor prognosis. This data would further substantiate abandonment of second look laparotomy and the investigation of maintenance therapies in this population. No significant financial relationships to disclose.
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
Authors: Suzanne Louise Topalian, Julie R. Brahmer, F. Stephen Hodi, David F. McDermott, David C. Smith, Scott N. Gettinger, Janis M. Taube, Charles G. Drake, Drew M. Pardoll, Scott Antonia, David R. Spigel, Michael B. Atkins, Donald P. Lawrence, Dan McDonald, Maria Jure-Kunkel, Alan Korman, Georgia Kollia, Ashok Kumar Gupta, Jon Wigginton, Mario Sznol
Journal: Journal of Clinical Oncology (2012)

CRA2509 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
Intravascular lymphomatosis of the CNS responds to initial treatment with CNOP and rituximab
Authors: C. J. Shamah, J. M. Connelly, M. G. Malkin, N. B. Davis
Journal: Journal of Clinical Oncology (2005)

6743 Background: Intravascular lymphomatosis (IVL) is a neoplastic proliferation of lymphoid cells within the lumen of blood vessels with little or no parenchymal involvement. It is rare, has a poor prognosis, and is often diagnosed post-mortem. Combination chemotherapy is the mainstay of treatment with mixed results. Recent case reports show effective treatment with chemotherapy or rituximab. However, none have used the combination of chemotherapy with rituximab as initial treatment of IVL. We present a case of dramatic clinical and radiographic improvement after two cycles of cyclophosphamide, mitoxantrone, vincristine, prednisone, and rituximab (CNOP-R.) Methods: Case Report Results: A 62-year-old-man presented with involuntary, uncontrollable head movements, progressing to left hemiparesis. Past medical history was noncontributory. Physical exam was unremarkable. Lumbar puncture revealed elevated protein. A thorough vasculitis and infection workup was negative. MRI of the brain showed multiple enhancing lesions. Craniotomy with brain biopsy of lesions was performed. Histological examination showed intraluminal clusters of cells with large, pleomorphic nuclei and prominent eosinophilic nucleoli. These cells were strongly CD20 and CD45 positive and CD3 negative. They were not observed outside blood vessels or in the brain parenchyma. A staging workup consisting of CT scans, bone scan, bone marrow biopsy and aspirate with cytogenetics did not reveal another involved site. Eight days after diagnosis, his clinical condition deteriorated with seizures and left neglect. MRI showed enlarging brain lesions. CNOP-R was started; mitoxantrone (N) replaced doxorubicin (H) due to borderline cardiac function. Symptoms improved after one day of treatment. After two cycles of CNOP-R, only mild weakness remained. Brain MRI showed partial response. Conclusions: This case represents the first report of initial treatment of IVL with CNOP-R. It demonstrates that early diagnosis and treatment of IVL can result in excellent clinical and radiographic Results: While further followup of this patient is warranted, CNOP-R should be considered as first line line therapy in CNS IVL. No significant financial relationships to disclose.
PET-based mapping of lymph node spread in lung cancer (NSCLC)
Authors: D. B. Landau, S. Ahmad, M. O'Doherty, T. Treasure
Journal: Journal of Clinical Oncology (2004)

7187 Background: The aim of this study was to investigate the pattern of mediastinal nodal involvement in NSCLC in relation to primary tumour location using PET imaging. Methods: A database of 800 patients scanned for suspected lung cancer was studied. The locations of the primary tumour and of any nodal metastases were noted. Nodes were considered positive if the uptake was significantly raised relative to the surrounding region. The study was intended to generate hypotheses for potential areas of research. Results: UZ = upper zone, MZ = mid-zone, LZ = lower zone, IH = ipsilateral hilar, SC = subcarinal, TB = tracheobronchial, PT = paratracheal, CH = contralateral hilar, AP/SM = Aortopulmonary /Superior Mediastinal, N+ = node positive. In IHN positive patients 14%, 6% and 23% respectively of UZ, MZ and LZ tumours showed increased activity in the SCN, 11%, 6% and 5% in the TBN and 17%, 7% and 14% in the CHN. In IHN negative patients the corresponding figures were 18%, 27% and 70% for SCN, 14%, 18% and 0% for TBN and 21%, 18% and 10% for CHN. Increased activity was seen in the TBN and SCN of 24 and 55 patients respectively, only 5 of these in the same patients. Conclusions: Hypotheses consistent with these results are: 1. IHN involvement is similar regardless of primary tumour location. 2. SC nodal involvement is more common with LZ tumours. 3. TB nodal involvement is more common with UZ tumours. 4. The CH nodes are more commonly involved than other nodal areas more frequently sampled or treated in routine clinical practice. This could mean that some NSCLC patients are significantly undertreated. 5. The TB and SC node groups might represent 2nd station nodes of distinct lymphatic pathways from IH nodes. These results give valuable information for further research into patterns of nodal spread in NSCLC aimed at improving radiotherapy and surgical planning. No significant financial relationships to disclose.
Potential diagnostic markers in bronchial fluid of small cell lung cancer (SCLC)
Authors: S. Carrera Revilla, A. Muñoz, R. Zalacain, G. López-Vivanco, M. Uribarri, L. Simón, B. Calvo, M. Jangi, I. Rubio, A. Ruiz de Lobera
Journal: Journal of Clinical Oncology (2009)

e22221 Background: Lung cancer is a major cause of mortality worldwide and overall survival rate has not improved significantly over the past 20 years. An early diagnosis could improve prognosis and survival among these patients. The aim of this study was to identify protein markers obtained from bronchial fluids of SCLC patients which may differ from non-pathological bronchoscopy samples. Methods: We have included 43 patients with SCLC diagnosed using bronchoscope and 49 consecutive patients with non pathological bronchoscopy. Bronquial fluid was obtained from each patient and potential protein markers were studied. After being centrifuged, supernatant proteins were analysed using bidimensional electrophoresis with poliacrilamid gel stained with silver nitrate. Gel was scanned and analysed with Progenesis PG6220 program, which measures intensity of each spot. Resultant intensities in each group of patients (SCLC/non pathological bronchoscopy) were compared using T-Student method. We selected as potential markers those spots with a p value of less than 0.05. We calculated “fold change” of each spot as the ratio between mean intensity in SCLC bronchoscopy samples and non pathological bronchoscopy samples. Results: Optimal bidimensional gels of each sample were obtained. Among 300 comparable spots, 10 of them were expressed with a different intensity in both groups of patients; 6 of these potential markers were over expressed in SCLC samples, whereas 4 of them were underexpressed. The “fold change” of these 10 spots ranges from 1.5 to 8.67. Conclusions: Different protein markers can be detected in bronchial fluid obtained from SCLC samples. Significant differences in expression of these biomarkers were detected between SCLC patients and non pathological bronchoscopy patients. The development of an early diagnostic test using these proteins must be validated in future studies. No significant financial relationships to disclose.
Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study
Authors: K. R. Rai, J. Moore, J. Wu, S. C. Novick, S. M. O'Brien
Journal: Journal of Clinical Oncology (2008)

7008 Background: Bcl-2 upregulation is critical in the pathogenesis and progression of CLL. OBL enhances the cytotoxic activity of agents used for CLL, including fludarabine (F) and cyclophosphamide (C). In a recent Phase 3 trial, patients (pts) who received OBL+FC (N=120) versus FC (N=121) achieved a significantly greater rate of complete response (CR, defined as CR plus nPR; primary endpoint) (O'Brien et al, J Clin Oncol 2007). CR duration was also superior for OBL+FC-treated pts. We evaluated whether these benefits would translate into improved survival for CR pts. Methods: Pts received ≤ 6 cycles of FC with/without OBL (3 mg/kg/d x 7d by continuous IV infusion beginning 4 days before FC). NCI-WG response was determined by blinded expert review. Five-year follow-up data will be collected for CR pts, and landmark analyses of the probability of maintaining CR and surviving performed (ITT population). Results: OBL+FC significantly increased the CR rate (17%) versus FC (7%) (P=0.025). CR duration was also significantly greater for OBL+FC (median not reached [estimated 36+ mos] versus FC [22 mos]) (P=0.031). In both groups, CR was associated with relief from all predefined CLL symptoms for ≥180 days (P<0.0001). Among CR pts at 54 months, 12/20 OBL+FC pts and 3/8 FC pts were still alive. CR was continuing in 5/12 OBL+FC pts versus 0/3 FC pts. Median survival among OBL+FC CR pts had not been reached (estimated 55+ mos) versus 45 months in FC pts. Conclusions: The addition of OBL to FC significantly increased CR rate and CR duration. The OBL+FC group had a higher probability of CRs with long survival than the FC group. CR is a valuable primary endpoint in relapsed/refractory CLL trials. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genta Incorporated Genta Incorporated Genta Incorporated Bayer, Celgene, Genentech™ BioOncology Bayer, Berlex Oncology, BioGen IDEC, Bristol-Myers Squibb, Eli Lilly, GeminX, Genentech™ BioOncology, Genta, Novartis
Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.
Authors: Yu-Tzu Tai, Laurence Catley, Xian-Feng Li, Rory Coffey, Iris Breitkreutz, Jooeun Bae, Klaus Podar, Teru Hideshima, Dharminder Chauhan, Robert Schlossman, Paul Richardson, Steven P. Treon, Iqbal S. Grewal2, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2005)
Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)
Authors: M. W. Verrill, J. Lee, D. A. Cameron, R. Agrawal, R. E. Coleman, K. McAdam, A. Wardley, A. Bowman, L. Ferrigan, A. Yellowlees
Journal: Journal of Clinical Oncology (2007)

LBA1005 Background: Phase II studies of weekly paclitaxel (P) confirm this to be a well tolerated regimen in ABC with potentially superior efficacy to standard q3w schedules. This was tested in the phase III CALGB 9840 trial, which used a “patient resource conserving” design, combining randomised patients with imported control data from a previous CALGB study of predominantly 2nd line treatment. This and the higher total dose of P in the weekly arm, left many unsure if there really was superior activity for the weekly schedule. Methods: The primary efficacy objective was to detect a 2 month improvement (6 to 8 months, HR = 1.33) in time to progression (TTP) by the giving the same total dose of P weekly (wP) vs. 3 weekly (3wP). 560 randomised patients were required to give 90% power to detect this difference at the 0.05 significance level. A single analysis was planned six months after study closure. Secondary endpoints include overall survival, toxicity and quality of life. The primary translational endpoint is a pharmacogenetic (PG) study of the effect of MDR and CYP single nucleotide polymorphisms. Between Sept. 2002 and July 2006, 569 patients were randomized to receive either wP 90 mg/m 2 for 12 weeks or 3wP 175 mg/m 2 for 6 cycles. Patients were stratified for measurable disease, prior treatment for ABC and Trastuzumab use. Results: The investigator reported response rates were 27% (3wP) and 42% (wP), p=0.002. Median TTP was 22.0 weeks for 3wP (95% CI 19.7–24.6) and 23.9 weeks for wP (95% CI 20.7–26.7), HR=0.92, p=0.06. Both schedules were well tolerated. PG samples from 325 patients are being matched to the unblinded efficacy data. Conclusions: This phase III trial shows that, for a matched total dose, wP produces a higher response rate than 3wP. This confirms the result from CALGB 9840. The mismatch in treatment duration in this trial may explain why TTP with wP was superior in CALGB 9840 while in the current study we have failed to detect superiority despite a higher response rate. Combining the trial results supports the hypothesis that total dose and schedule of P are important. Our results support the widespread adoption of wP as the standard schedule. No significant financial relationships to disclose.